Transjugular liver biopsy in the 1990s: a 2-year audit
Article first published online: 24 DEC 2001
Alimentary Pharmacology & Therapeutics
Volume 13, Issue 5, pages 603–608, May 1999
How to Cite
PAPATHEODORIDIS, PATCH, WATKINSON, TIBBALLS and BURROUGHS (1999), Transjugular liver biopsy in the 1990s: a 2-year audit. Alimentary Pharmacology & Therapeutics, 13: 603–608. doi: 10.1046/j.1365-2036.1999.00514.x
- Issue published online: 24 DEC 2001
- Article first published online: 24 DEC 2001
: In view of the changing nature of transjugular liver biopsy, we performed an audit of the safety, adequacy and clinical impact of such biopsies in our centre over a 2-year period from 1995 to 1997.
: One hundred and fifty-seven transjugular biopsies were carried out in 145 patients, with prothrombin time >5 s over control and/or platelet count <50 × 109/L and/or gross ascites.
: Major complications were two (1.3%) capsular perforations, which were easily plugged with coils without sequelae. Biopsy sample was adequate for histological diagnosis in 90%, inadequate in 6% and technically unsuccessful in 4% of cases. Mean biopsy size was 14.8 ± 7.7 (1–51) mm. Adequacy did not differ between cases with and without cirrhosis. Transjugular biopsy had a clinical impact (specific diagnosis or influence on patient’s management) in 50% of acute liver disease, 62% of chronic liver disease and 87% of transplant patients (P < 0.001). In chronic liver disease, it had a significantly greater clinical impact in cases trying to establish the stage rather than diagnosis (84% vs. 35%, P < 0.001).
: Transjugular liver biopsy is a safe procedure for high-risk patients providing an adequate liver sample even in cirrhosis. It has a clinical impact in more than 80% of transplant patients and for staging chronic liver disease, but in only 50% (acute) or 35% (chronic) of liver disease when a diagnosis is sought.